Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: The Fierce 50 of 2024
Shingrix
Pharma
GSK cuts 2024 vaccines sales amid CDC's narrowed RSV policy
Despite limited RSV vaccination policy and disappointing Shingrix sales in Q2, GSK maintained Arexvy's peak sales projection and upped group guidance.
Angus Liu
Jul 31, 2024 10:13am
GSK's Arexvy dominates RSV market ahead of new competition
May 1, 2024 11:20am
Big Pharma reworks China strategy, and job cuts are part of it
Dec 22, 2023 8:22am
GSK crushed Pfizer in first round of RSV vaccine showdown
Nov 1, 2023 10:43am
ESMO: Searching for the perfect cup of pharma-branded espress-MO
Oct 20, 2023 7:59am
GSK partners up with Zhifei to market Shingrix in China
Oct 9, 2023 11:20am
